EntreMed’s pipeline contains a balanced portfolio of clinical product candidates and promising preclinical compounds. The portfolio contains compounds that work primarily through multiple mechanisms of action (MOA) and have demonstrated potential in both oncology and inflammatory disease.

The Company’s pipeline consists of two product candidates (Panzem^® (2-methoxyestradiol or 2ME2) NCD and MKC-1) in multiple Phase 2 oncology studies, a Phase 1 oncology product candidate (ENMD-1198), plus late-stage preclinical programs for an Aurora/angiogenesis inhibitor (ENMD-2076) for the treatment of cancer, and Panzem for the treatment of rheumatoid arthritis.

EntreMed’s Pipeline

EntreMed’s pipeline offers promising and unique product candidates for continued development and commercialization for the following reasons:

Multiple Mechanisms of Action
Working through multiple mechanisms of action, EntreMed’s drug candidates have the potential to attack cancer cells through multiple pathways that affect the formation and replication of tumor cells, and can interrupt the formation of blood vessels that nourish tumor cells and sustain tumor growth. EntreMed has pursued tumor indications where multiple mechanisms of action provide a competitive advantage and could provide proof-of-concept data to support the design of pivotal trials.

Versatility
While the Company’s preclinical and clinical efforts continue to focus on oncology, EntreMed believes that other diseases characterized by angiogenesis represent future opportunities.

The company has positioned Panzem® NCD as a combination therapy with approved antiangiogenic and cytotoxic agents. Preclinical studies have shown that Panzem^®, as a cytostatic agent with a favorable safety profile, has an additive or synergistic effect on tumor inhibition when used in combination with radiation or approved chemotherapeutic agents at their maximum tolerated dose (MTD), without an increase in toxicity. This is a unique feature that we intend to continue pursuing throughout Panzem^®’s clinical development.

Convenient Dosing
EntreMed is developing drug candidates that will be easy to use as compared to other modes of drug administration. The Company is focusing specifically on oral drug delivery technologies.

Intellectual Property Position
All EntreMed pipeline programs are backed by strong intellectual property rights. Each product candidate is covered by issued or pending composition, method and use patents. The Company owns or has licensed over 50 patent applications and issued patents in the United States for our product candidates. The Company has well over 100 pending patent applications and issued patents in the United States and other countries.

EntreMed’s pipeline is a blend of compounds that were either discovered internally or licensed from third parties. Panzem^® (2ME2) is licensed from Children’s Medical Center Corporation, the tubulin inhibitor program is licensed from Celgene Corporation, and MKC-1 is licensed from Roche. Other compounds were discovered and developed internally and, as a result, are EntreMed’s sole property. EntreMed has retained commercial rights to all compounds.